Dennis Plenker worked as the Senior Director of Research & Innovation at Xilis Inc. He earned his Ph.D. in genetics at the Institute of Translational Genomics at the University of Cologne. Dennis is passionate about using ex vivo patient models for functional precision medicine, drug discovery with relevant biology, toxicology and to ultimately improve patient care and enable new biology.
At Cold Spring Harbor Laboratory, Dennis led the human 3D organoid platform, where he and his team established more than 100 organoids for the Human Cancer Model Initiative, contributing to a collection of more than 330 human organoids from various cancers, pre-cancerous lesions and normal tissue. His work included building and operating high-throughput screening platforms, developing optimized reagents for 3D cultures, and helping to initiate the PASS-01 clinical trial (NCT04469556) to evaluate the clinical feasibility and translation of organoids.
Since then, Dennis worked at the Organoid group at Loxo Oncology at Lilly before transitioning to Xilis in 2022. At Xilis, Dennis has driven technology development, diagnostics and the technical translation of patient-derived models using MicroOrganoSpheres (MOS). His responsibilities included evaluating the feasibility of MOS technology for partnerships, method optimization, diagnostic applications, and assay development.
Dennis is passionate about innovation and advancing the boundaries
of science and technology and the recent progress in the field, including the FDA's passage of the Modernization Act 2.0, which opens new possibilities for alternative testing methods in drug development. In addition, Dennis is active in the Society of Laboratory Automation and Screening (SLAS) for which he is a short course instructor since 2024 and track chair for cellular technologies helping to organize SLAS 2027.
Read More